NUCLEIX

Nucleix develops, manufactures, and markets non-invasive cancer tests designed to support earlier detection, when treatment may be most effective. The company works with leading medical centers, organizations, and laboratories around the world to advance its diagnostic technologies and bring testing options to patients and healthcare systems.

Its Bladder EpiCheck test is available in Europe for primary and recurrent bladder cancer and upper urinary tract cancer. In the United States, it has received FDA 510(k) clearance for monitoring recurrence of non-muscle invasive bladder cancer. Nucleix also has Lung EpiCheck in development, with the goal of detecting early-stage lung cancer in high-risk individuals through a blood test.

At the heart of its work is the EpiCheck platform, which the company describes as enabling highly accurate and sensitive results with a seamless testing option. Nucleix’s research and development capabilities are intended to support the creation of additional liquid biopsy assays for other cancer types. Through these products and collaborations, the company focuses on expanding non-invasive approaches to cancer detection and monitoring.